Boosting the synergism between cancer ferroptosis and immunotherapy via targeted stimuli-responsive liposomes

Biomaterials. 2024 Mar:305:122442. doi: 10.1016/j.biomaterials.2023.122442. Epub 2023 Dec 20.

Abstract

Both ferroptotic therapy and immunotherapy have been widely employed in cancer treatment. However, ferroptotic cell death fails to induce dendritic cells maturation, which limits the therapeutic outcome of ferroptotic cancer therapy. To address this, the current work reports a tailored liposome to establish a positive loop between ferroptotic therapy and immunotherapy. As the key component of liposome, a unique phospholipid is designed to bear two arachidonic acid tails. The liposome is further surface-engineered with fucose ligand and physically encapsulates immunostimulatory CpG oligodeoxynucleotides (ODNs). The tailored liposome shows enhanced cellular uptake in a model 4T1 cell line. Meanwhile, the high level of reactive oxygen species in cancer cells can induce ferroptosis-specific peroxidation of DAPC and trigger the release CpG ODNs. The CpG ODNs further enable the maturation of dendritic cells and enhance the effector function of CD8+ T cells. IFN-γ released from CD8+ T cells promotes cancer cell ferroptosis via inhibiting SLC7A11 and suppressing the biosynthesis of glutathione. The tailored liposome can also act in synergism with PD-L1 antibody, resulting in enhanced anti-cancer efficacy in a 4T1 tumor-bearing mice model. This work provides a promising strategy for cancer treatment through orchestrating ferroptotic therapy and immunotherapy.

Keywords: Ferroptosis; Immunotherapy; Lipid peroxidation; Liposomes; Stimuli-responsive.

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes
  • Cell Line, Tumor
  • Ferroptosis*
  • Immunotherapy
  • Liposomes
  • Mice
  • Neoplasms* / therapy

Substances

  • Liposomes